{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016616","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.516429+00:00","generated_at":"2026-06-02T01:41:24.953679+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCardia Q1 net loss narrows to $2.3M; CardiAMP HF 86% mortality reduction in subgroup","bullets":["Q1 net loss $2.3M vs $3.5M YoY; revenue $55K; operating cash burn $1.5M (improved from $2.6M).","CardiAMP HF interim: 86% relative risk reduction in mortality for elevated NTproBNP subgroup; final data Q4 2024.","Confirmatory Phase III HF II trial activated Q1; 250-patient, >90% powered, enrollment goal 2 years.","CardiALLO low dose cohort completed with no adverse events; partnership with StemCardia for Phase I/II.","Morph-DNA steerable sheath FDA submission on track for Q2 2024; expected approval Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016616","json":"https://secwatch.observer/filing/0001437749-24-016616.json","markdown":"https://secwatch.observer/filing/0001437749-24-016616.md","text":"https://secwatch.observer/filing/0001437749-24-016616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/0001437749-24-016616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/bcda20240513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:41:24.953679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0d207b896f0926098d366db8191056053cc4b56","claim":"BioCardia, Inc. reported first quarter of 2024 results: revenue approximately $55,000.","evidence_excerpt":"Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/0001437749-24-016616-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"approximately $55,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}